- |||||||||| remdesivir / Generic mfg., dexamethasone / Generic mfg.
DEVELOPMENT OF MIS-A IN A FULLY VACCINATED PATIENT WITH COVID-19 INFECTION: VACCINE LIMITATIONS () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1405;
After completing her vaccination series, our patient developed COVID-19 infection and subsequent MIS-A. To our knowledge, this is the first reported case of MIS-A in a fully vaccinated patient, adding to the literature that vaccinations, though they prevent severe COVID-19 infection, may not completely prevent the development of rare long-term complications.
- |||||||||| REFRACTORY TOXIC SHOCK SYNDROME: IV IMMUNOGLOBULIN TO THE RESCUE! () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1400;
She received fluid resuscitation and was initiated on empiric antibiotic therapy with clindamycin, piperacillin-tazobactam and vancomycin...Despite multiple wound debridement and amikacin therapy, patient failed to improve clinically...She was premedicated with diphenhydramine, hydrocortisone, and acetaminophen...IVIG can be effective in treating TSS refractory to conventional treatment by neutralizing superantigens. The efficacy of IVIG in treating TSS has been variable across multiple studies, but our case highlights the efficacy of IVIG in toxic shock syndrome refractory to standard therapy.
- |||||||||| dexamethasone / Generic mfg., prednisone / Generic mfg.
CLINICAL CHARACTERISTICS OF STRONGYLOIDIASIS DURING THE COVID-19 PANDEMIC: SYSTEMATIC SCOPING REVIEW () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1391;
Likely due to COVID-19-related eosinopenia and the effect of corticosteroids, patients may not necessarily have overt eosinophilia despite the parasitic infection. Developing a Strongyloides screening strategy for COVID-19 patients based on patients’ demographics and origins may help diagnose the condition.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
EVALUATION OF TOCILIZUMAB ON CLINICAL OUTCOMES IN CRITICALLY ILL PATIENTS WITH COVID-19 () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1380;
In this retrospective study evaluating tocilizumab in addition to dexamethasone for severe COVID-19 treated in the ICU, tocilizumab did not show a benefit in clinical outcomes. Given the size of the study and its limitations, these findings should be interpreted with caution and require confirmation by larger studies.
- |||||||||| dexamethasone / Generic mfg., prednisone / Generic mfg.
ANALYZING TREND OF INFLAMMATORY MARKERS IN COVID-19 PATIENTS () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1371;
This study showed that ferritin peak occurred slightly later than CRP and LDH. We can anticipate ferritin to have a slightly longer course to peak.
- |||||||||| ivermectin oral / Generic mfg.
DISSEMINATED STRONGYLOIODES INFECTION AFTER CORTICOSTEROID USE () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1368;
Strongyloides hyperinfection is an uncommon complication with a high mortality rate, with meningeal involvement often described post-mortem. Prophylactic anti-parasitic agents can be considered for patients identified as high risk for chronic strongyloidiasis who are about to undergo corticosteroid treatments, including COVID-19 associated regimens.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
TOCILIZUMAB FOR COVID-19 IN THE MEDICAL INTENSIVE CARE UNIT: MATERNAL AND FETAL OUTCOMES () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1337;
Based on this case series, tocilizumab seems to be a safe option for pregnant woman and subsequently their babies, with no severe complications or deformities noted during birth. However, 71.4% of patients did undergo preterm labor, prompting future research into whether these is any correlation between tocilizumab and preterm labor.
- |||||||||| Olumiant (baricitinib) / Incyte, Eli Lilly, Actemra IV (tocilizumab) / Roche, JW Pharma
BARICITINIB VERSUS TOCILIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19 () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1331;
There was no significant difference in the composite outcome of progression to mechanical ventilation or in-hospital mortality in patients who received TCZ of BARI for the treatment of COVID-19. However, this primary outcome occurred more frequently in the TCZ group, and a larger study may be able to detect this difference.
- |||||||||| Cytovene (ganciclovir) / Roche
A CASE OF CMV POLYRADICULOMYELITIS IN AN IMMUNOCOMPETENT PATIENT () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1327;
The patient developed symptoms weeks after admission, indicating that it was likely his critical illness that put him at high risk for reactivation of a latent infection. Additionally, diffuse transverse myelitis placed him at high risk for respiratory compromise and irreversible respiratory failure.
- |||||||||| dexamethasone injection / Generic mfg.
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A HIDDEN SURPRISE UNDER THE GARB OF DENGUE FEVER? () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1323;
She was started on intravenous Dexamethasone 10 mg twice a day...In patients with worsening liver injury and hematological indices, the differential should be tailored towards secondary HLH. A high suspicion for HLH and timely evaluation of its markers can be instrumental in improving survival in this cohort as evidenced in our case.
- |||||||||| dexamethasone / Generic mfg.
EVALUATION OF CORTICOSTEROID USE AND SECONDARY INFECTION RATES IN CRITICALLY ILL COVID-19 PATIENTS () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1298;
In patients who received corticosteroids for COVID-19, exceeding recommended dosing strategies by either prolonging treatment or receiving higher cumulative doses was associated with increased rates of SI. Patients with SI were more likely to experience increased ICU LOS, ventilator days and mortality.
- |||||||||| Berinert (C1 esterase inhibitor (human) IV) / CSL Behring, Firazyr (icatibant) / Takeda, Kalbitor (ecallantide) / Takeda
ANGIOEDEMA PREVENTING EXTUBATION IN A CASE OF ACQUIRED C-1 ESTERASE DEFICIENCY () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1290;
Epinephrine and Solumedrol were administered, however the neck swelling worsened and the patient was intubated for airway protection...Glucocorticoids were ineffective as the patient had a reported allergy to Prednisone, therefore were further avoided...If Berinert is ineffective, some immunologists and allergists have seen favorable outcomes and recommend treatment with the kallikrein inhibitor, ecallantide and the bradykinin B2 antagonist icatibant. To date, therapies targeted at prevention of angioedema in acquired cases have not been as successful as in hereditary forms, therefore, treatment is directed at the underlying condition, such as immunotherapy or chemotherapy for CLL.
- |||||||||| Sylvant (siltuximab) / Jazz, Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI
PROFOUND EPISTAXIS IN CYTOKINE RELEASE SYNDROME FOLLOWING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1283;
He progressed with worsening hypotension and encephalopathy and was admitted to the ICU and required vasopressors, pulse-dose steroids, and siltuximab...Effective and timely treatment of bleeding associated with DIC and severe CRS can be life-saving. It behooves the intensivist to recognize the toxicities of CAR-T as therapeutic applications broaden in the coming years.
- |||||||||| Olumiant (baricitinib) / Incyte, Eli Lilly
THERAPEUTIC USE OF BARICITINIB IN COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1278;
Introduction: The reduction of mortality in COVID-19 has been clinically established only for Dexamethasone and Tocilizumab to date, but the overall mortality in COVID-19 remains high. Baricitinib used along with the standard of care treatments is associated with a reduction in mortality in hospitalized patients with COVID-19 disease.
- |||||||||| HYPERTHYROIDISM MASKED BY ACUTE CHOLECYSTITIS WITH RESULTING THYROID STORM () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1149;
The presence of new-onset delirium with hemodynamic instability post-operatively should raise a high index of suspicion for thyroid storm and must be treated without delay. Maintaining a broad differential prior to surgical intervention, a known trigger, could propel the clinician into considering underlying thyroid pathologies and prevent thyroid storm altogether.
- |||||||||| ceftriaxone / Generic mfg., dexamethasone injection / Generic mfg.
Journal: Hypopharyngeal perforation caused by blunt trauma in buffalo attack. (Pubmed Central) - Jan 25, 2023
The decision was made to manage the patient conservatively with intravenous dexamethasone and intravenous ceftriaxone/metronidazole for antibiotic prophylaxis. The patient had his diet gradually upgraded and was discharged home 4 days later with oral amoxicillin and clavulanic acid.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Yescarta (axicabtagene ciloleucel) / Gilead, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Acute myeloid Leukemia after Anti-CD19 CAR-T Therapy in a Patient with Relapsed High-grade non-Hodgkin B Lymphoma (Breakout room, Hybrid) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_259;
Initial complications included tumor flare-up symptoms, grade 2 CRS (requiring 1 dose of Tocilizumab on day +11), and grade 1 neurotoxicity (received dexamethasone 6mg on day +13 with improvement of symptoms)...Myeloid panel sequencing of DNA from peripheral blood revealed a mutation in CEBPA that was not identified in a DNA sample from time of DLBCL diagnosis.We hypothesize that myeloid disease developed from a small coexisting clone at the start of CAR-T therapy. To our knowledge, this is the second case of AML development in a post-CAR-T DLBCL relapse.
- |||||||||| Kymriah (tisagenlecleucel-T) / Novartis, Actemra IV (tocilizumab) / Roche, JW Pharma
CAR-T for Central Nervous System Lymphoma (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_141;
For the appearance of ICANS g1 on day +4 (ICE score 8), she received treatment with dexamethasone (10 mg x 4/die)...A PET-scan documented a systemic progression of the disease. Unfortunately, on day +35 the patient died for lymphoma progression.Despite the inefficacy of CAR-T treatment even in presence of CAR-T cells in liquor, we were able to infuse CAR-T cells in a safe condition for the patient (obtaining CNS negativity before CAR-T cell infusion), and ICANS was well controlled with an early toxicity treatment approach.Figure1: "Ependymal thickening in a post contrast FLAIR image in suspicious brain lymphomatous progression"
- |||||||||| Sinus Bradycardia: A Symptom of ICANS after CAR T-cell Therapy (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_138;
ICANS °IV may be linked to overall dysfunction of the blood brain barrier, with disruption of several functions of CNS, including autonomous regions causing severe sinus bradycardia. Another situation of CNS dysfunction appears during epileptic seizures, where simultaneous occurrence of sinus bradycardia/arrythmia has been observed as well.
- |||||||||| Thrombopoietin Receptor Agonist after Anti-CD19 CAR-T Cells: A Case Report (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_111;
In this single-case experience, thrombopoietin receptor agonist has proven effective and safe as therapy for prolonged cytopenias after CAR-T infusions. Prospective studies are needed to confirm the potential of this strategy.
- |||||||||| ISIKOK-19 / Acıbadem Healthcare, Acıbadem University
ISIKOK-19 CAR T Cell in ALL with Extramedullary Disease (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_102;
P1/2
In conclusion, the administration of ISIKOK-19 CAR-T therapy in this small patient group with EMD achieved safety and efficacy outcomes. These preliminary results make us believe that ISIKOK-19 CAR-T constitutes a potential therapeutic option in such a high unmet medical need.
- |||||||||| Sylvant (siltuximab) / Jazz, Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI
CRS after CAR-T Cell Therapy for MCL: A Case Report (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_96;
After 34 days, he was extubated without neurologic deficits, but with myopathy and colonization of resistant Gram-negative bacteria. One month post CAR-T cell therapy, complete remission (CR) was achieved, and the patient was discharged.
- |||||||||| Kineret (anakinra) / SOBI
Neurotoxicity of CD19-CAR-T-Cells: A Case Report (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_93;
This case report demonstrates high efficacy of anti-CD19 CAR-T-cell therapy in a patient with high-risk DLBCL and CNS involvement with a well-documented expansion and persistence of CAR-T-cells in blood and CSF. To treat the severe neurotoxicity a second line with anakinra was effective.
- |||||||||| Yescarta (axicabtagene ciloleucel) / Gilead
A Newly Reported ICANS-associated MRI Alteration after CAR-T Cell Therapy (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_92;
Reversible punctuates inflammation of the body and splenium of the corpus callosum may represent a novel radiological finding of CAR T-cell therapy-related neurotoxicity. Descriptions of novel distinctive investigative features are pivotal to defining a neuroradiological signature that would inform diagnosis and pathophysiology.Figure 1: Brain MRI findings.Axial (A) and sagittal (B) 1.5 Tesla T2-weighted fluid-attenuated inversion recovery (FLAIR) showed multiple focal punctuate areas of hyperintensities in the splenium and isthmus of the corpus callosum, with no contrast enhancement or diffusion restriction.
- |||||||||| s-AML with KMT2A Rearrangement Following CAR-T for R/R DLBCL (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_91;
He developed grade 4 thrombocytopenia, grade 2 cytokine release syndrome, and grade 2 immune-cell associated neurotoxicity syndrome, which were managed with tocilizumab and dexamethasone, respectively...At this point treatment with Azacitidine-Venetoclax was planned as a bridge to Allogeneic Hematopoietic Stem Cell Transplant in first remission, but unfortunately, the patient died of progressive leukemia and sepsis due to treatment delay after SARS-COV2 infection.This clinical case highlights the need to bring CAR-T therapy to earlier treatment lines in relapsed/refractory DLBCL. Second-line approval of CAR-T therapies can bypass potentially fatal complications that may arise from exposure to high-dose salvage treatment, such as Secondary Acute Myeloid Leukemia.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Yescarta (axicabtagene ciloleucel) / Gilead, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
CECs in CAR-T cells Associated CRS and ICANS (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_78;
She developed early grade 1 CRS on day +1 which was treated with tocilizumab 8 mg/kg...On day+7, she developed grade 2 ICANS that rapidly progressed to grade 3 ICANS with akinetic mutism, requiring 24 hours-ICU admission and steroids (dexamethasone 20 mg/6h)...We found that CECs/CEPs levels were increased at the time of ICANS development. Analysis of serum endothelial biomarkers (VEGF-A,angiopoietin-2,VCAM-1,PAI-1,vWF) could be presented at the meeting.Fig.1:CECs/CEPs before and after CAR-T infusion
- |||||||||| The Endothelium Involvement during CRS: First Reported Case of CAR-VOD (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_76;
Following 4.6*106 CAR-T cells/kg infusion, multiple complications ensued:CRS maximum grade 2, characterized by persistent fever (>72 hours) not responsive to antipyretics (ferritin max 9124 ug/L; C-reactive protein max 174.1 mg/L, IL-6 max 598 pg/mL), leading to tocilizumab administration on day 4 (1 dose).Hepatic toxicity: VOD-like hepatic involvement (starting on day 2) with fulfillment of 3 out of 5 EBMT pediatric diagnostic criteria (definitive diagnosis D4): increased weight >5% above baseline, elevated bilirubin >5 mg/dl within 72 h, and ascites on the abdominal ultrasound imaging. This case of "CAR-VOD" contributes to the ongoing discussion about endothelial damage in CRS and ushers the debate about the emerging concept of endothelial protection into the context of hyperinflammation after cellular therapies.
- |||||||||| Kymriah (tisagenlecleucel-T) / Novartis, Actemra IV (tocilizumab) / Roche, JW Pharma
Early Management CRS and Outcome of DLBCL Treated with CAR-T (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_68;
Fifty-four patients treated with either axicabtagén ciloleucel (n=31) or tisagenlecleucel (n=23) were included...Tocilizumab was administered in the majority of patients who had CRS (83.3%, n=45) and dexamethasone was used in 29 cases (53.7%)... In our experience, the early management of cytokine release syndrome could avoid the development of severe CRS in high risk patients, without affecting CAR-T cell response or increasing neurological toxicity.
- |||||||||| Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
First Real World Data from the Austrian CAR-T Network (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_53;
This first real-world retrospective analysis of selected AT-CAR-T patients based on a defined algorithm demonstrates favorable outcomes and is comparable to other approaches using centralized selection criteria, e.g., with the French DESCAR-T data. Our data support that co-morbidities and fitness of CAR-T candidates need to be acknowledged and substantiate that a nationwide selection algorithm can serve as a consensual approach for local patient allocation. The limitation of our data is the relatively small patient cohort and lack of outcome data for individuals who didn't receive CAR-T cell therapy based on the AT-CAR-T algorithm.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Calquence (acalabrutinib) / AstraZeneca
Durable Responses Assessment after Brexu-cel for R/R MCL in ZUMA-2 (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_40;
P2
After ~3-year median follow-up, brexu-cel continues to demonstrate durable responses with 49% of patients in ongoing response at 24 months post infusion. Ongoing responders had lower ECOG scores and tumor burden, less frequent bridging therapy use, and less intense regimens for previous relapses, suggesting potential for greater benefit with brexu-cel if given in earlier course of disease.
- |||||||||| prednisolone / Generic mfg.
Review, Journal, Checkpoint inhibition: Immune Checkpoint Inhibitors and Optic Neuropathy: A Systematic Review. (Pubmed Central) - Jan 24, 2023
The only two patients who achieved full resolution of symptoms were treated with oral prednisolone...Although it remains uncommon, the incidence of optic neuropathy in this population exceeds that of the general population. Future research is needed to further characterise the risk profiles of patients who are most likely to develop ICI-associated optic neuropathy, and treatment pathways for these patients.
- |||||||||| dexamethasone / Generic mfg.
Journal, IO biomarker: Ginsenoside Rg3 treats acute radiation proctitis through the TLR4/MyD88/NF-κB pathway and regulation of intestinal flora. (Pubmed Central) - Jan 24, 2023
Wistar rats were randomly divided into control, model, dexamethasone-positive, GRg3 low-dose, GRg3 medium-dose, and GRg3 high-dose groups...After GRg3 treatment, the mRNA and protein expression of TLR4, MyD88, and NF-κB in rectal tissue was significantly down-regulated, and the level of downstream inflammatory factor IL-1β decreased, whereas that of IL-10 increased. Our study indicated GRg3 as a new compound for the treatment of ARP by inhibiting the TLR4/MyD88/NF-κB pathway, down-regulating the expression of proinflammatory factors, thus effectively regulating intestinal flora and reducing inflammatory reactions.
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: Transcription analyses of differentially expressed mRNAs, lncRNAs, circRNAs, and miRNAs in the growth plate of rats with glucocorticoid-induced growth retardation. (Pubmed Central) - Jan 24, 2023
In this study, 2-week-old male Sprague-Dawley rats had been treated with 2 mg/kg/d of dexamethasone for 7 or 14 days, after which the growth plate tissues were collected for high-throughput RNA sequencing to identify differentially expressed mRNAs, lncRNAs, circRNAs, and miRNAs in GIGR rats...Moreover, the constructed ceRNA networks suggested that several miRNAs (including miR-140-3p and miR-127-3p) might play an important role in the pathogenesis of GIGR. These results provide new insights and important clues for exploring the molecular mechanisms underlying GIGR.
- |||||||||| dexamethasone / Generic mfg.
Journal: Sex-Dimorphic Glucocorticoid Receptor Regulation of Hypothalamic Primary Astrocyte Glycogen Metabolism: Interaction with Norepinephrine. (Pubmed Central) - Jan 24, 2023
The glucocorticoid receptor (GR) agonist dexamethasone (DEX) down-regulated glycogen synthase (GS), glycogen phosphorylase (GP)-brain type (GPbb), and GP-muscle type (GPmm) proteins in glucose-supplied male astrocytes, but enhanced these profiles in female...Results document GR modulation of NE stimulation of glycogen accumulation in the presence (male and female) or absence (female) of glucose. Outcomes provide novel proof that astrocyte energy status influences the magnitude of GR and NE signal effects on glycogen mass.
- |||||||||| dexamethasone / Generic mfg.
Journal: Tetramethylpyrazine ameliorates acute lung injury by regulating the Rac1/LIMK1 signaling pathway. (Pubmed Central) - Jan 24, 2023
The mice in treatment groups had TMP or dexamethasone administered intraperitoneally 30 min prior to the 1st hit and 30 min past the 2nd hit...Our findings show that using TMP during sepsis can protect the pulmonary microvascular endothelial cell barrier and suppress inflammation. Therefore, TMP may have a promising therapeutic role in preventing acute lung injury from sepsis.
- |||||||||| budesonide / Generic mfg.
Journal: Etiological spectrum of isolated ileo-cecal ulcers in patients with gastrointestinal symptoms. (Pubmed Central) - Jan 24, 2023
Based on clinical, colonoscopic, and histopathological findings, initial treatment was symptomatic/antibiotics in 55%, anti-tubercular treatment in 21%, 5-aminosalicylic acid/steroids for CD in 13%, oral budesonide in 10% of patients, and one patient was referred for management of malignancy...The majority of these ulcers harbor underlying significant diseases that can cause morbidity and mortality if left undiagnosed and untreated. Reaching a specific diagnosis in such cases is not straightforward, and patients are often subjected to repeat examinations.
- |||||||||| hydrocortisone / Generic mfg., favipiravir / Generic mfg.
Retrospective data, Journal: Characteristics, outcomes, and risk factors for in-hospital mortality of COVID-19 patients: A retrospective study in Thailand. (Pubmed Central) - Jan 24, 2023
Favipiravir (86%) was the main antiviral treatment...Admission to the ICU was the only factor associated with reduced mortality [odds ratio (OR) 0.01, 95% confidence interval (CI) 0.01-0.05, P < 0.001], whereas older age (OR 14.3, 95%CI 5.76-35.54, P < 0.001), high flow nasal cannula (HFNC; OR 9.2, 95% CI 3.9-21.6, P < 0.001), mechanical ventilation (OR 269.39, 95%CI 3.6-2173.63, P < 0.001), septic shock (OR 7.79, 95%CI, 2.01-30.18, P = 0.003), and hydrocortisone treatment (OR 27.01, 95%CI 5.29-138.31, P < 0.001) were factors associated with in-hospital mortality...The only factor associated with reduced mortality was admission to the ICU. Therefore, appropriate selection of patients for admission to the ICU, strategies to limit disease progression and prevent intubation, and early detection and prompt treatment of nosocomial infection can improve survival in these patients.
- |||||||||| budesonide / Generic mfg.
Review, Journal, Surgery: Managing ulcerative colitis after surgery. (Pubmed Central) - Jan 24, 2023
Antibiotics are the elective treatment for acute pouchitis, but regarding chronic pouchitis, this condition is very complicated to treat due to the absence of well-designed specific studies for this group of patients. Antibiotics, budesonide, and biological therapies are some of the recommended drugs for these patients, but despite their use, some need a permanent ileostomy.
|
